# Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/acquired-rare-recurrent-i-egfr-i-mutations-as-mechanisms-of-resistance-to/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Lin Lin,Qiang Lu,Ran Cao,Qiuxiang Ou,Yutong Ma,Hua Bao,Xue Wu,Yang Shao,Zhaoxia Wang,Bo Shen |
| Citations | 20 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/7716156 |
| OpenAlex ID | https://openalex.org/W3112920278 |
| PMID | 33294282 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Qiang Lu](https://scholariq.org/researchers/qiang-lu-2/)

## Paper journal

- [PubMed](https://scholariq.org/journals/pubmed/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.